SHIEF (Shield Therapeutics) GF Value : $0.07 (As of Mar. 30, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Shield Therapeutics GF Value?

As of today (2025-03-30), Shield Therapeutics's share price is $0.034. Shield Therapeutics's GF Value is $0.07. Therefore, Shield Therapeutics's Price-to-GF-Value for today is 0.49. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Shield Therapeutics is Possible Value Trap, Think Twice.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Shield Therapeutics (OTCPK:SHIEF) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Shield Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.034	/	0.07
	=	0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (OTCPK:SHIEF) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

STX:UK 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Shield Therapeutics Headlines

From GuruFocus

Full Year 2023 Shield Therapeutics PLC Earnings Presentation Transcript

By GuruFocus Research • 05-01-2024

Full Year 2023 Shield Therapeutics PLC Trading Statement Presentation Transcript

By GuruFocus Research • 03-01-2024

Half Year 2024 Shield Therapeutics PLC Earnings Presentation Transcript

By GuruFocus Research • 09-05-2024